OpenURL Connection Search

Select item for more details and to access through your institution.

Prediction of a clinically effective dose of THY1773, a novel V1Breceptor antagonist, based on preclinical data.
Published in:
Biopharmaceutics & Drug Disposition, 2021, v. 42, n. 5, p. 204, doi. 10.1002/bdd.2273
By:
- Inatani, Shoko;
- Mizuno‐Yasuhira, Akiko;
- Kamiya, Makoto;
- Nishino, Izumi;
- Sabia, Helene D.;
- Endo, Hiromi
Publication type:
Article
Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials.
Published in:
BMC Psychiatry, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12888-022-03785-7
By:
- Inoue, Yuichi;
- Uchiyama, Makoto;
- Umeuchi, Hideo;
- Onishi, Koichi;
- Ogo, Hiroki;
- Kitajima, Iwao;
- Matsushita, Isao;
- Nishino, Izumi;
- Uchimura, Naohisa
Publication type:
Article
Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer 11C-TASP699.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262430
By:
- Naganawa, Mika;
- Nabulsi, Nabeel B.;
- Matuskey, David;
- Henry, Shannan;
- Ropchan, Jim;
- Shu-Fei Lin;
- Gao, Hong;
- Pracitto, Richard;
- Labaree, David;
- Ming-Rong Zhang;
- Suhara, Tetsuya;
- Nishino, Izumi;
- Sabia, Helene;
- Ozaki, Satoshi;
- Huang, Yiyun;
- Carson, Richard E.
Publication type:
Article
Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer 11C-TASP699.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262430
By:
- Naganawa, Mika;
- Nabulsi, Nabeel B.;
- Matuskey, David;
- Henry, Shannan;
- Ropchan, Jim;
- Shu-Fei Lin;
- Hong Gao;
- Pracitto, Richard;
- Labaree, David;
- Ming-Rong Zhang;
- Tetsuya Suhara;
- Izumi Nishino;
- Sabia, Helene;
- Satoshi Ozaki;
- Yiyun Huang;
- Carson, Richard E.
Publication type:
Article
Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer 11C-TASP699.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262430
By:
- Naganawa, Mika;
- Nabulsi, Nabeel B.;
- Matuskey, David;
- Henry, Shannan;
- Ropchan, Jim;
- Shu-Fei Lin;
- Hong Gao;
- Pracitto, Richard;
- Labaree, David;
- Ming-Rong Zhang;
- Tetsuya Suhara;
- Izumi Nishino;
- Sabia, Helene;
- Satoshi Ozaki;
- Yiyun Huang;
- Carson, Richard E.
Publication type:
Article
Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer 11C-TASP699.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262430
By:
- Mika Naganawa;
- Nabulsi, Nabeel B.;
- Matuskey, David;
- Henry, Shannan;
- Ropchan, Jim;
- Shu-Fei Lin;
- Hong Gao;
- Pracitto, Richard;
- Labaree, David;
- Ming-Rong Zhang;
- Tetsuya Suhara;
- Izumi Nishino;
- Sabia, Helene;
- Satoshi Ozaki;
- Yiyun Huang;
- Carson, Richard E.
Publication type:
Article
Validity and reliability of a driving simulator for evaluating the influence of medicinal drugs on driving performance.
Published in:
Psychopharmacology, 2021, v. 238, n. 3, p. 775, doi. 10.1007/s00213-020-05730-6
By:
- Iwata, Mari;
- Iwamoto, Kunihiro;
- Kitajima, Iwao;
- Nogi, Takasuke;
- Onishi, Koichi;
- Kajiyama, Yu;
- Nishino, Izumi;
- Ando, Masahiko;
- Ozaki, Norio
Publication type:
Article
Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand, [11C]TASP457.
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 4, p. 1127, doi. 10.1007/s00259-021-05571-1
By:
- Kimura, Yasuyuki;
- Takahata, Keisuke;
- Shimazaki, Toshiharu;
- Kitamura, Soichiro;
- Seki, Chie;
- Ikoma, Yoko;
- Ichise, Masanori;
- Kawamura, Kazunori;
- Yamada, Makiko;
- Zhang, Ming-Rong;
- Higuchi, Makoto;
- Nishino, Izumi;
- Suhara, Tetsuya
Publication type:
Article
Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder.
Published in:
BMC Psychiatry, 2020, v. 20, n. 1, p. N.PAG, doi. 10.1186/s12888-020-02932-2
By:
- Saito, Takuya;
- Yamashita, Yushiro;
- Tomoda, Akemi;
- Okada, Takashi;
- Umeuchi, Hideo;
- Iwamori, Saki;
- Shinoda, Satoru;
- Mizuno-Yasuhira, Akiko;
- Urano, Hidetoshi;
- Nishino, Izumi;
- Saito, Kazuhiko
Publication type:
Article

Found: 9

Prediction of a clinically effective dose of THY1773, a novel V<sub>1B</sub>receptor antagonist, based on preclinical data.

Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials.

Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer <sup>11</sup>C-TASP699.

Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer <sup>11</sup>C-TASP699.

Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer <sup>11</sup>C-TASP699.

Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer <sup>11</sup>C-TASP699.

Validity and reliability of a driving simulator for evaluating the influence of medicinal drugs on driving performance.

Pharmacokinetic and pharmacodynamic assessment of histamine H<sub>3</sub> receptor occupancy by enerisant: a human PET study with a novel H<sub>3</sub> binding ligand, [<sup>11</sup>C]TASP457.

Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder.